[18F]AlF-Bi-PSMA

[18F]AlF-Bi-PSMA is a next-generation radiopharmaceutical designed for positron emission tomography (PET) imaging and potentially therapy of prostate cancer. It consists of a bispecific small molecule ligand that targets the prostate-specific membrane antigen (PSMA), which is highly expressed on the surface of most prostate cancer cells, and is labeled with fluorine-18 via an aluminum fluoride chelation method. The drug enables precise targeting and visualization of PSMA-expressing tumors, facilitating both diagnosis and monitoring of disease progression or response to therapy. Its mechanism involves binding to PSMA on tumor cells, allowing for targeted delivery of the radioactive isotope for imaging or therapeutic purposes. This approach aims to improve specificity, in-vivo stability, and tumor uptake compared to earlier generation agents[3][5]. The primary indication under investigation is metastatic castration-resistant prostate cancer (mCRPC).

Other names

[18F]AlF-bisphosphonate PSMA18F-Aluminum fluoride bisphosphonate PSMA